Control of Fluoroquinolone Resistance through Successful Regulation, Australia
Allen C. Cheng, John Turnidge, Peter Collignon, David Looke, Mary Barton, and Thomas Gottlieb
Author affiliations: Monash University, Melbourne, Victoria, Australia (A.C. Cheng); Alfred Hospital, Melbourne (A.C. Cheng); Women’s and Children’s Hospital, Adelaide, South Australia, Australia (J. Turnidge); University of Adelaide, Adelaide (J. Turnidge); The Canberra Hospital, Garran, Canberra, Australia (P. Collignon); Australian National University, Canberra (P. Collignon); Princess Alexandra Hospital, Brisbane, Queensland, Australia (D. Looke); University of Queensland, Brisbane (D. Looke); University of South Australia, Adelaide (M. Barton); Concord Hospital, Sydney, New South Wales, Australia (T. Gottlieb); and University of Sydney, Sydney (T. Gottlieb)
Figure 1. . . Data from Drug Utilization Sub-Committee Drug Utilization Database on Pharmaceutical Benefits Scheme and the Repatriation Pharmaceutical Benefits Scheme (RPBS) on subsidized medicines and estimates of non-subsidized medicines. RPBS data were calculated from continuous data on all prescriptions dispensed from a validated sample of community-based pharmacies. In-patient hospital prescribing is not included. Usage rate calculated on the basis of medication use of 1,000 persons per day. DDD, defined daily dose.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.